This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
PERJETA is a HER2/neu receptor antagonist indicated for:
Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Use in combination with trastuzumab and chemotherapy as:
o Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
o Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
If a patient becomes pregnant while receiving PERJETA and Herceptin, or within 7 months following the last dose of PERJETA and Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.